Abstract
People with endometriosis use cannabis to manage their symptoms. This study aimed to identify costs, modes of administration, product composition, and self-reported effectiveness for those accessing medicinal cannabis in Australia. There were 192 survey responses analysed. Most (63.5%) used a ‘cannabis clinic’ doctor, incurring an initial consultation cost of $100-$200+ (10.2% Medicare bulk-billed) and median cannabinoid medicine costs of $300AUD per month. Cost was a major barrier to access, necessitating reducing dosage (76.1%) and/or consuming illicit cannabis (42.9%), despite a prescription. Most (77%) medical consumers used two or more cannabis products, with delta-9-tetrahydrocannabinol predominant oil and flower products most frequently prescribed.
Keywords: CBMP, administration method, cannabis, chronic pain, dose, endometriosis, insurance
© 2024 The Authors. Australian and New Zealand Journal of Obstetrics and Gynaecology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
References
REFERENCES
-
- Rowlands IJ, Abbott JA, Montgomery GW et al. Prevalence and incidence of endometriosis in Australian women: A data linkage cohort study. BJOG 2021; 128(4): 657-665.
-
- Armour M, Lawson K, Wood A et al. The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: A national online survey. PLoS One 2019; 14(10): e0223316.
-
- Evans S, Villegas V, Dowding C et al. Treatment use and satisfaction in Australian women with endometriosis: A mixed-methods study. Intern Med J 2021; 52: 2096-2106.
-
- Sinclair J, Toufaili Y, Gock S et al. Cannabis use for endometriosis: Clinical and legal challenges in Australia and New Zealand. Cannabis Cannabinoid Res 2021; 7: 464-472.
-
- Armour M, Sinclair J, Cheng J et al. Endometriosis and cannabis consumption during the COVID-19 pandemic: An international cross-sectional survey. Cannabis Cannabinoid Res 2022; 7(4): 473-481.